Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Macaya Douoguih, Paul Goepfert et al.|New England Journal of Medicine|2022Cited by 250
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, An Vandebosch et al.|The Lancet Infectious Diseases|2022Cited by 88
Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐ and HPV18‐induced infections and diseaseSelina Khan, Jerome Custers|International Journal of Cancer|2017Cited by 26